GlassScriptPhysician profile
Lisa S Vernon
NPI 1447223128
$2,585.04
in general payments reported to CMS, 2019-2025
33 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $275 · 2021: $233 · 2022: $244 · 2023: $716 · 2024: $476 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.85 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $515.25 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $351.27 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Sumitomo Pharma America, INC. | $211.08 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $133.73 | 2019-2024 | Myosure Tissue Removal Device, Aptima |
| Baxter Healthcare | $110.23 | 2023-2024 | Perclot |
| Coopersurgical, INC. | $106.82 | 2022-2023 | Endosee |
| Amgen INC. | $87.22 | 2022-2025 | Evenity |
| Therapeuticsmd, INC. | $78.42 | 2019-2022 | |
| Roche Diagnostics Corporation | $75.42 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $73.07 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.92 | 2020-2025 | |
| Evofem Biosciences, INC. | $68.68 | 2020-2024 | Phexxi |
| Medline Industries LP | $60.02 | 2023 | |
| Organon LLC | $57.36 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.76 | 2025 | Xifaxan |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $50.51 | 2021-2022 | |
| Myovant Sciences INC. | $44.91 | 2022 | |
| Millicent US INC | $43.31 | 2019-2025 | Femlyv, Intrarosa |
| Pfizer INC. | $42.17 | 2021-2023 | |
| Amag Pharmaceuticals, INC. | $41.18 | 2019 | |
| Daiichi Sankyo INC. | $41.14 | 2024 | Injectafer |
| Exact Sciences Corporation | $37.33 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $37.23 | 2019-2020 | |
| Sage Therapeutics, LLC | $30.47 | 2024-2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $27.56 | 2019-2020 | |
| Glaxosmithkline, LLC. | $26.92 | 2020-2021 | |
| Pacira Pharmaceuticals Incorporated | $25.97 | 2020-2022 | |
| Duchesnay USA Incorporated | $25.59 | 2019 | |
| Smith+Nephew, INC. | $17.12 | 2023 | Pico 7 |
| Supernus Pharmaceuticals, INC. | $15.15 | 2025 | Qelbree |
| Exeltis, USA INC. | $13.66 | 2020 | |
| Medicem INC. | $13.57 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Vernon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.